Welcome to our dedicated page for Adma Biologics SEC filings (Ticker: ADMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ADMA Biologics' SEC filings document its specialty biologics business through Form 8-K reports on operating and financial results, FDA-related disclosures for ASCENIV, Regulation FD materials and other material-event updates. These records include disclosures tied to product revenue trends, immune globulin market conditions, commercial distribution, plasma collection and biomanufacturing operations.
ADMA's definitive proxy materials cover annual meeting matters, board and governance proposals, voting procedures and executive compensation. Its current reports also document executive transitions, related agreements, capital-structure matters, share-repurchase activity and risk-oriented product disclosures associated with immune globulin products.
ADMA Biologics, Inc. reported voting results from its 2026 Annual Meeting of Stockholders held on June 2, 2026. As of the April 8, 2026 record date, 232,324,283 common shares were outstanding, and 199,267,547 shares were represented virtually or by proxy, constituting a quorum.
Stockholders elected Class I directors Alison C. Finger and Eduardo Rene Salas. Finger received 156,849,830 votes for and 19,376,842 votes withheld, with 23,040,875 broker non-votes. Salas received 171,947,523 votes for and 4,279,149 votes withheld, with the same broker non-votes.
Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with 198,655,040 votes for, 329,056 against, and 283,451 abstentions. On a non-binding advisory basis, the Say-on-Pay proposal for named executive officer compensation was approved, receiving 168,169,866 votes for, 7,730,690 against, 326,116 abstentions, and 23,040,875 broker non-votes.
ADMA Biologics director Jerrold B. Grossman reported buying 6,400 shares of common stock at $7.91 per share in an open-market transaction on May 27, 2026. Following this purchase, his directly held position, including 10,690 restricted stock units and 509,594 common shares, totaled 520,284 shares.
He also reported indirect holdings of ADMA common stock through several related entities and relationships: 175 shares held by Brookwood LLC, 38,294 shares held by the Jerrold Grossman 2019 Irrevocable Trust, 31,381 shares held by Genesis Foundation Inc., and 22,857 shares held by his wife.
ADMA Biologics director Jerrold B. Grossman bought additional shares of company stock. On May 12, 2026, he made an open-market purchase of 12,500 shares of ADMA common stock at $8.01 per share. Following this transaction, he directly holds 513,884 common shares, which includes 10,690 RSUs granted on February 9, 2026 that vest in two equal installments on August 9, 2026 and February 9, 2027, along with 503,194 owned shares. He also has several indirect holdings: 175 shares through Brookwood LLC, 38,294 shares through the Jerrold Grossman 2019 Irrevocable Trust, 31,381 shares held by Genesis Foundation Inc., and 22,857 shares owned by his wife.
ADMA Biologics director Jerrold B. Grossman bought 12,500 shares of common stock in an open-market transaction at $8.01 per share. Following this purchase, his directly owned stake shown in the filing increased to 501,384 shares of ADMA common stock.
The filing also lists additional ADMA shares held indirectly through Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and his wife, reflecting interests associated with the director beyond his direct holdings.
ADMA Biologics reported strong profitability on flat revenue for the quarter ended March 31, 2026. Total revenue was $114.5 million, essentially unchanged year over year, but product mix shifted sharply. ASCENIV sales rose to $97.5 million, up 27.7%, while other IVIG and intermediates declined.
Gross profit increased to $80.8 million and gross margin expanded significantly, helped by ASCENIV growth and the new yield‑enhanced manufacturing process. Net income rose to $45.3 million, compared with $26.9 million a year earlier, with diluted EPS of $0.19.
ADMA used leverage to fund capital returns. It drew $125.0 million on its JPM revolving facility and repurchased 6.8 million shares for $111.1 million, including an accelerated share repurchase. Cash ended at $138.2 million, while total debt increased to $196.9 million.
The company also sold three plasma centers for $12.0 million, recognizing about $8.0 million gain, and later obtained FDA approval to expand ASCENIV’s label to children two years and older.
ADMA Biologics reported first quarter 2026 results showing flat revenue but sharply higher profitability. Total revenue was $114.5 million, essentially unchanged from $114.8 million a year earlier, as 28% growth in ASCENIV sales to $97.5 million offset a 54% decline in revenue from another immunoglobulin product and lower intermediates revenue.
Gross profit rose to $80.8 million and gross margin expanded to 71% from 53%, helped by a richer ASCENIV mix and prior manufacturing improvements. GAAP net income increased to $45.3 million from $26.9 million, while Adjusted Net Income reached $40.7 million and Adjusted EBITDA was $59.7 million, both growing more than 20% year over year. The company generated $58 million of operating cash flow and ended March 31, 2026 with $138.2 million of cash and cash equivalents.
Management reiterated confidence in ASCENIV demand and updated its full-year 2026 outlook to reflect competitive pressure in the U.S. immunoglobulin and plasma therapies market, while withdrawing longer-term guidance.
ADMA Biologics reports a key regulatory milestone for its ASCENIV immune globulin therapy. The U.S. Food and Drug Administration has approved a supplemental Biologics License Application expanding ASCENIV’s primary humoral immunodeficiency indication to pediatric and adult patients two years of age and older, from a prior minimum age of 12 years. The approval also fulfills the required pediatric post‑marketing commitment and allows updated prescribing information. ASCENIV is a patented, plasma-derived intravenous immune globulin designed to provide antibodies against infections, supported by an established safety profile that includes boxed warnings and detailed precautions typical for IVIG products.
ADMA Biologics Inc ownership update: Vanguard Capital Management reports beneficial ownership of 12,110,153 shares of Common Stock, representing 5.08% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 12,110,153 shares and sole voting power for 1,803,282 shares. The filing is signed by a Vanguard representative on 04/29/2026.
ADMA Biologics, Inc. is calling a virtual 2026 annual stockholder meeting on June 2, 2026 at 10:00 a.m. Eastern Time via www.virtualshareholdermeeting.com/ADMA2026. Stockholders of record at the close of business on April 8, 2026, when 232,324,283 common shares were outstanding, may vote.
Investors will vote on electing two Class I directors, ratifying KPMG LLP as independent auditor for 2026, and approving on an advisory basis the compensation of named executive officers. The board, which currently has seven members in three staggered classes, recommends voting FOR all proposals.
The proxy describes ADMA’s governance structure, including fully independent Audit, Compensation, and Governance and Nominations Committees, and highlights a pay-for-performance philosophy that combines base salary, annual incentives, and multi-year equity awards. It also discloses major stockholders and equity plan capacity.